Oxford Biomedica PLC Total Voting Rights (9804A)
December 31 2014 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 9804A
Oxford Biomedica PLC
31 December 2014
TOTAL VOTING RIGHTS
Oxford, UK - 31 December 2014: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), announces that in
accordance with the FCA's Disclosure and Transparency Rule 5.6.1,
the Company's issued share capital consists of 2,565,896,766
ordinary shares of 1 pence each ("Ordinary Shares"). There are no
Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in Oxford
BioMedica plc at the date of this notice is 2,565,896,766.
The above figure (2,565,896,766) may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, Oxford BioMedica plc under the FCA's Disclosure
and Transparency Rules
-Ends-
For further information, please
contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer Tel: +44 (0)1865
Tim Watts, Chief Financial Officer 783 000
Media Enquiries:
Mary-Jane Elliott/Matthew Neal/Chris Tel: +44 (0)20
Welsh/Laura Thornton 3709 5700
Consilium Strategic Communications
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy company with an unrivalled portfolio of gene therapy
products in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Company's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Company has licenced products
and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions and ImaginAb. Further information is
available at www.oxfordbiomedica.co.uk and
www.oxbsolutions.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAPAEDLKLFFF
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024